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ABSTRACT
Background Age-related macular degeneration (AMD)
remains the most common cause of visual loss among
subjects over 50 years of age in the developed world.
The Irish Longitudinal study on Ageing (TILDA) is a
population-based study of subjects aged 50 years or
older, designed to investigate factors that inﬂuence
ageing, and has enabled this investigation of the
prevalence of AMD in the Republic of Ireland (ROI).
Methods Data collected from a nationally
representative sample of community-living older adults
aged 50 years and over in ROI over the period November
2009 to July 2011. 5035 participants attended the
TILDA health centre for assessment. Retinal photographs
were obtained in 4859 of these participants. Retinal
grading was performed in a masked fashion using a
modiﬁed version of the International Classiﬁcation and
Grading System for AMD.
Results Adjusting for lower response rates among older
subjects, the estimated overall prevalence of any AMD
was 7.2% (95% CI 6.5% to 7.9%) in the population
aged 50 years or older. The estimated prevalence of
early AMD was 6.6% (95% CI 5.9% to 7.3%), and the
estimated prevalence of late AMD was 0.6% (95% CI
0.4% to 0.8%). Statistically signiﬁcant associations with
AMD included increasing age and family history of the
condition.
Conclusions This is the ﬁrst study to provide
prevalence estimates of AMD in ROI and will inform eye
care professionals and policymakers involved in the
delivery and planning of care for those afﬂicted with this
condition.
INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blind registration in the developed
world. In the Republic of Ireland (ROI), AMD is
estimated to account for 25% of all blind registra-
tion (57.1 per 100 000 adults).1 Early AMD is
characterised by drusen and/or pigmentary abnor-
malities, whereas the late (advanced) form of AMD
is visually consequential and can be classed as atro-
phic (geographic atrophy) or neovascular.2
Subjects with early AMD beneﬁt from antioxi-
dant supplementation, in terms of reduced risk of
visual loss and disease progression.3 4 Currently,
there is no effective treatment for atrophic AMD,
whereas neovascular AMD is treated by intravitreal
injections of antivascular endothelial growth factor
therapy.5 6 The ongoing nature of treatment for
neovascular AMD has profound cost implications
to patients and to society, reﬂected in the recent
retrospective observational study that demonstrated
that new cases of neovascular AMD were associated
with substantial discrepancies in total medical costs
(41% higher compared with non-neovascular AMD
controls).7 The cost implications for neovascular
AMD treatment are, however, balanced against
savings associated with this treatment (improve-
ment in visual acuity and reduction in cases of legal
blindness).8 Patients with untreated or untreatable
advanced AMD invariably suffer from impairment
of central vision, with consequential loss of social
independence as a result of a concomitant inability
to read, recognise faces, watch television or drive.9
The Irish Longitudinal Study on Ageing (TILDA,
http://www.tilda.ie)10 is a prospective cohort study
aimed at providing representative and comprehen-
sive data relating to older people and the ageing
population in ROI, by collecting data on the social,
economic and health status of participants aged
50 years and over. At baseline (wave 1), TILDA col-
lected vision data, including retinal photographs for
grading of AMD, as part of the health assessment.
Although the prevalence of AMD has been
reported in population-based studies for many dif-
ferent countries,11 12 the TILDA sample provides an
unprecedented opportunity to investigate the preva-
lence of AMD from a population-based random
sample selected from ROI.
MATERIALS AND METHODS
Study population
The design and methodology of TILDA has been
described in detail elsewhere.10 The TILDA sam-
pling frame was based on a comprehensive record of
all residential addresses in ROI compiled by the
Irish Postal Service (An Post) and Ordnance Survey
Ireland (RANSAM system, developed by the
Economic and Social Research Institute of Ireland),
and the sampling method was designed to achieve a
population-representative sample of (community-
resident) individuals aged 50 years or older. The
sampling frame was made up of 3155 clusters (500–
1180 residential addresses in each cluster). A total
of 640 clusters were randomly selected using pro-
portionate stratiﬁcation by socioeconomic status
(percentage in professional/managerial occupa-
tions), age structure (percentage of population aged
50 years or older) and geography. Forty residential
addresses were randomly selected from each of the
640 clusters, resulting in a list of 25 600 addresses.
A letter of invitation was sent to each of the sampled
addresses, furnishing residents with information
about the study and informing residents of the
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proposed visit by a member of the ﬁeld staff. All sampled
addresses were then visited by a member of the ﬁeld staff, and
residents that were deemed eligible were then invited to partici-
pate. All persons aged 50 years and over (primary respondents)
and their spouses or partners of any age (secondary respondents)
were eligible for inclusion in TILDA. Of note, secondary respon-
dents are not included in this analysis.
In all, 8504 participants were sampled, with 8175 partici-
pants aged 50 years or older. Enrolled participants completed
the computer-assisted personal interviewing questionnaire, self-
completion questionnaires and were offered either a health
centre assessment or a home-based assessment.10 13 Of note,
5035 (62%) participants underwent a health centre assessment,
which included retinal photographs for AMD grading. Figure 1
illustrates the TILDA baseline (wave 1) participants included in
the current study. Data for this report were collected as part of
the ﬁrst wave of TILDA, which was initiated in October 2009,
and completed in July 2011.
Retinal photography
Retinal photography was carried out using the NIDEK AFC-210
non-mydriatic auto-fundus camera, through a non-dilated pupil,
by TILDA research nurses. TILDA nurses were trained and certi-
ﬁed by experts from the Ocular Epidemiology Reading Centre at
the University of Wisconsin, Madison, USA. One 45° monoscopic
colour photograph, centred on the macula (Early Treatment
Diabetic Retinopathy Study standard ﬁeld 2), was obtained for
each eye. The photographs were anonymised using a unique iden-
tiﬁer and transferred to the Moorﬁelds Eye Hospital (MEH)
Reading Centre, London, UK (http://www.readingcentre.org) and
the Macular Pigment Research Group (MPRG, http://www.mprg.
ie), Vision Research Centre, Waterford, Ireland.
Retinal grading
Retinal photographs were graded at MPRG, Vision Research
Centre, Waterford, Ireland, by a masked grader (KOA) who was
trained and certiﬁed at the MEH Reading Centre. Grading was
carried out under the supervision of the MEH Reading centre
manager (TP) using a modiﬁed version of the International
Classiﬁcation and Grading System for AMD.2
The following AMD features were evaluated: the presence of
>10 hard drusen (<63 mm), soft drusen (>125 mm), atrophic
AMD and signs of neovascular AMD (choroidal neovascularisa-
tion, retinal pigment epithelium detachment, disciform scar).
Early AMD was deﬁned as the presence of >10 hard drusen
(<63 mm) and/or the presence of soft drusen (>125 mm). Late
AMD was deﬁned as the presence of atrophic AMD and/or neo-
vascular AMD. Mixed AMD was deﬁned as the presence of atro-
phic AMD in one eye and neovascular AMD in the other eye.
AMD features graded as questionable were adjudicated by the
MEH Reading Centre. To ensure that valid and reliable data
with respect to AMD grading were secured, the following
quality assurance measures were taken: ﬁrst, 10% of images
were regraded by the MEH Reading Centre for concordance.
Second, intragrader reliability was assessed by the regrading of a
3% randomly selected sample of retinal photographs graded by
the principal grader (KOA) with a minimum interval of 14 days
between visualisation of the images in question.
Statistical analysis
Statistical analysis was conducted using IBM SPSS Statistics for
Windows, V.20.0. Armonk, New York, New York, USA;
weighted kappa statistics, not available in SPSS, were obtained
using the statistical programming language R.14 For purposes of
statistical analysis, the worst eye, in terms of AMD severity, was
assigned to each participant.
Of 5035 TILDA participants who presented at health centres
for clinical examination, 4859 had retinal photographs for at
least one eye (right eye in 4808 and left eye in 4798). Intragrader
reliability was assessed in 300 eyes using the kappa statistic.
Demographic characteristics of participants with gradable photo-
graphs were compared with those with ungradable photographs
using independent samples t test or χ2 test of independence.
After excluding subjects with ungradable fundus photographs,
4751 participants remained for estimating AMD prevalence.
Selection of households for inclusion in this study was
random, but we identiﬁed two major sources of subsequent
bias. In addition to the usual non-response bias, common to
most social surveys, it was evident that non-attendance at health
Figure 1 A total of 8175 participants aged 50 years or older
completed the Irish Longitudinal study on Ageing (TILDA) baseline
(wave 1) interview. Health assessments were conducted in clinical
centres in Dublin and Cork, Republic of Ireland. Participants who
refused or were unable to attend clinical centres were given the option
of a home-based clinical assessment. Home-based clinical assessment
did not include retinal photography. Retinal photographs were taken at
the clinical centres using the NIDEK AFC-210 camera. Subjects with no
photographs were either due to the following reasons: unable,
unwilling and technical failure. Photographs were judged as ungradable
based on photographic quality.
1038 Akuffo KO, et al. Br J Ophthalmol 2015;99:1037–1044. doi:10.1136/bjophthalmol-2014-305768
Clinical science
group.bmj.com on November 9, 2017 - Published by http://bjo.bmj.com/Downloaded from 
centres was more common, for example, among older subjects,
and this introduced additional bias. In order to identify and
adjust for bias, study participants were initially classiﬁed by
three variables—age (three categories, 50–64, 65–74 and ≥75),
gender (male, female) and education (three categories, primary/
none, secondary and tertiary/higher), resulting in a total of 18
(3×2×3) sample subgroups. Comparison of numbers in these
subgroups, with what would be expected from the correspond-
ing data for the population of ROI (available from the Central
Statistics Ofﬁce, Dublin),15 revealed signiﬁcant discrepancies.
For instance, female, third-level educated and younger subjects
were over-represented in the sample. However, before develop-
ing sample weights to adjust for these discrepancies, we ﬁrst
used logistic regression to investigate the relationship between
AMD prevalence and these three variables jointly. As only the
age variable was signiﬁcantly related to AMD in the regression
analysis, sample weights, adjusting for disproportionate repre-
sentation, were calculated using just this (age) variable. These
weights were then applied in all calculations of overall AMD
prevalence.
The relationship between the prevalence of AMD, and estab-
lished or putative risk factors for this condition, other than age,
was investigated by logistic regression. Each such investigation
controlled for age and included an age*risk factor interaction
term. In reporting results, however, we elected to stratify by age
and report prevalence with respect to potential risk factors
within each age group. The 5% level of statistical signiﬁcance
was applied throughout all risk factor analyses, without adjust-
ment for multiple testing.
RESULTS
Demographic characteristics of the TILDA participants studied
as part of this investigation are reported in table 1. Participants
with ungradable photographs were signiﬁcantly older and had
poorer visual acuity compared with participants with gradable
photographs.
Intragrader reliability showed moderate agreement for all cat-
egories.16 Kappa and weighted kappa scores varied from 0.51
to 0.61 and 0.60 to 0.61, respectively. Exact agreement for
AMD features varied from 91% to 96%.
Prevalence of AMD
Increasing age was the only variable exhibiting a statistically sig-
niﬁcant association with AMD (deﬁned as any AMD yes/no) in
a logistic regression model including the variables age, gender
and education. The development of sample weights based on
this age variable is presented in table 2. The age group ≥75 con-
stitutes over 18% of the over 50s in the Irish population, but
only 8.5% of the sample reported herein. Therefore, ignoring
this under-representation in the sample of the oldest age group
would lead to an underestimate of prevalence of AMD. The
weights (ﬁnal column of table 2) adjust for this: every subject
aged ≥75 in the sample is treated (in estimating overall preva-
lence) as representing 544 subjects in the population, whereas
sample subjects in the other two age groups are treated as repre-
sentative of about 225 subjects in the population.
Table 3 shows the prevalence of each category of AMD, as
well as the estimated prevalence of AMD (all forms) for those
aged 50 years or older in ROI. These estimates are based on the
weights presented in table 2. Adjusting for age, the prevalence
of AMD (any form) was 7.2% (95% CI 6.5% to 7.9%); the
prevalence of early AMD was 6.6% (95% CI 5.9% to 7.3%);
the prevalence of late AMD was 0.6% (95% CI 0.4% to 0.8%);
the prevalence of atrophic AMD was 0.3% (95% CI 0.1% to
0.5%) and the prevalence of neovascular AMD was 0.3% (95%
CI 0.1% to 0.5%).
Analysis of AMD by other demographic subgroups, stratifying
by age, is shown in table 4. The p values displayed in table 4
were obtained from the χ2 test for contingency tables. Some dif-
ferences in prevalence of AMD are evident in table 4 with
Table 1 Demographic and other characteristics of TILDA baseline
(wave 1) participants included in study analyses
Characteristic Mean±SD
Age 61.61±8.10
BMI 28.42±4.51
VA 0.06±0.18
Characteristic n (%)
Gender
Male 2169 (45.7)
Female 2582 (54.3)
Total 4751 (100)
Education
Primary/none 1013 (21.3)
Secondary 1986 (41.8)
Tertiary/higher 1750 (36.8)
Total 4749 (100)
Location
Dublin 1383 (29.1)
Other urban 1259 (26.5)
Rural 2104 (44.3)
Total 4746 (100)
Smoking
Never 2189 (46.1)
Past 1856 (39.1)
Current 706 (14.9)
Total 4751 (100)
Family history
No/don’t know 4496 (94.6)
Yes 255 (5.4)
Total 4751 (100)
Cardiovascular disease
No 2987 (62.7)
Yes 1771 (37.3)
Total 4751 (100)
Stroke
No 4690 (98.7)
Yes 61 (1.3)
Total 4751 (100)
Interval data presented as mean±SD. Categorical data presented as percentages.
Cardiovascular disease refers to participants who reported no self-reported doctor’s
diagnosis of any of the following: angina, heart attack, heart failure, stroke, transient
ischaemic attack and heart murmur. Stroke refers to participants who reported a
doctor’s diagnosis of stroke.
Age, age in years; BMI, body mass index (kg/m2); Dublin, residence in Dublin city or
county; Other urban, residence in other urban, another town or city in the Republic of
Ireland; education, level of education; family history, subjects who reported a family
history of age-related macular degeneration (AMD)—family history was defined as
having a first-degree relative, that is, parent or sibling with AMD; location, location of
residence in the Republic of Ireland; primary/none, subjects who did not have
education and those with only primary education; rural, residence in rural area in the
Republic of Ireland; secondary, subjects who completed a junior certificate or leaving
certificate or equivalent; smoking, smoking status of subjects classified as never (no
reported history of smoking), past (past smokers) and current (current smokers);
tertiary, subjects who completed a diploma, first degree or higher degree; TILDA, the
Irish Longitudinal study on Ageing; VA, visual acuity; visual acuity recorded in
logarithm of the minimum angle of resolution (logMAR)—visual acuity was measured
in both eyes using an Early Treatment Diabetic Retinopathy Study logMAR chart at a
test distance of 4 m; only eye with best visual acuity is reported.
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respect to gender, education and geographic location (‘Dublin’
vs ‘other urban’ vs ‘rural’). However, a statistically signiﬁcant
difference was observed only for early AMD with respect to
geographic location (with prevalence values of 10.8%, 18.4%
and 6.3% of participants categorised as ‘Dublin’, ‘other urban’
and ‘rural’, respectively). Some other, statistically non-
signiﬁcant, ﬁndings in table 4 may be attributable to the small
sample sizes of the respective subgroups; for example, preva-
lence of (any and early) AMD is clearly greater for women than
for men in the ≥75 age group.
The prevalence of drusen within demographic subgroups,
stratifying by age, is reported in table 5.
Risk factors for (any) AMD
Each risk factor for AMD (as listed in table 1) was investigated
separately via logistic regression models containing that risk
factor; each such model also included age, and the interaction
of age with that risk factor. The dependent variable in these
analyses was any AMD (yes/no); logistic analyses for smaller cat-
egories of AMD were deemed statistically infeasible. Subjects
with ungradable photographs, and subjects unsure of family
history for AMD, were omitted from all regression analyses.
Age was highly statistically signiﬁcant in all logistic regression
analyses (p<0.005 in all analyses). Family history was also statis-
tically signiﬁcant (OR=0.28, 95% CI for OR=0.11 to 0.69,
p=0.006), but the age*family history interaction was not
(p=0.17). None of the other risk factors analysed (gender, edu-
cation, geographic location, body mass index (BMI), stroke, car-
diovascular disease, smoking), nor their respective interactions
with the age risk factor, were statistically signiﬁcant (p>0.05
for all). For example, we obtained p=0.10 for BMI and p=0.16
for the interaction term, p=0.44 for cardiovascular disease and
p=0.76 for the interaction, p=0.32 for stroke and p=0.38 for
the interaction.
We considered that the other risk factors merited further
exploration, beyond the basic regression ﬁndings, and that the
best way to do this was to stratify by age and analyse each risk
factor separately within each age group. Table 4 (ﬁrst three age
columns) contains this information for any AMD, and for each
of the three demographic risk factors (gender, education,
location). The p values displayed in table 4 were obtained from
the χ2 test for contingency tables; all p values exceed 0.05 and
so support the earlier ﬁndings from the logistic regression
analyses.
Positive family history was deﬁned as having a ﬁrst-degree
relative, that is, parent or sibling, with AMD. The relationship
of family history to (any) AMD, stratifying by age, is presented
in table 6. The prevalence of AMD was signiﬁcantly higher in
those who reported a positive family history in the age group
65–74 (14.5% with AMD, p=0.017) and ≥75 (33.3% with
AMD, p=0.002). These signiﬁcant ﬁndings support the earlier
ﬁndings from the logistic regression analysis.
The remaining risk factor (smoking) was not signiﬁcantly
associated with (any) AMD, after controlling for age (p=0.59
for smoking, p=0.44 for the interaction, in the logistic regres-
sion). Nevertheless, we have included some details of the
smoking–AMD relationship in table 6. While not statistically sig-
niﬁcant, it is worth noting that in all three age groups, in
table 6, prevalence of (any) AMD was higher for current
smokers than for either of the other smoking groups. It is also
worth reporting that, in the case of neovascular AMD (consist-
ently associated with smoking in the literature), six of nine
study subjects (67%) with this condition are past or current
smokers, whereas just 54% of the TILDA sample are past or
current smokers.
Other results
While logistic regression was not considered feasible for risk
factor analysis for the rarer forms of AMD, table 4 has some
interesting contingency table results for these. A statistically sig-
niﬁcant difference was observed for early AMD with respect to
geographic location (with prevalence values of 10.8%, 18.4%
and 6.3% of participants categorised as ‘Dublin’, ‘other urban’
and ‘rural’, respectively). Some other, statistically non-
signiﬁcant, ﬁndings in table 4 may be attributable to the small
sample sizes of the respective subgroups; for example, preva-
lence of any AMD (and also early AMD) is clearly greater for
women than for men in the ≥75 age group.
The prevalence of drusen within demographic subgroups,
stratifying by age, is reported in table 5. There are three statistic-
ally signiﬁcant results highlighted in table 5, but in general,
deﬁnitive conclusions based on table 5 results (as in tables 4
and 6) are problematic because of the small numbers of subjects
in certain subgroups.
DISCUSSION
This study was undertaken to investigate the prevalence of
AMD in ROI using the TILDA wave 1 (baseline) sample.
Subjects were randomly selected from the ROI population and
therefore representative of the community-dwelling population
Table 2 Sample weights for analysis
Age group Population (%) Sample (%) Weight
50–64 700 800 (58.4) 3093 (65.1) 226.6
65–74 280 900 (23.4) 1256 (26.4) 223.6
≥75 218 700 (18.2) 402 (8.5) 544.0
Weights developed from age variable. Population data were based on the Republic of
Ireland population census 2011.
Table 3 Prevalence of age-related macular degeneration (AMD) by age category
Age groups (years)
Any AMD Early AMD Late AMD Atrophic AMD Neovascular AMD Mixed AMD*
n (%) n (%) n (%) n (%) n (%) n (%)
50–64 156 (5.0) 152 (4.9) 4 (0.1) 1 (0.0) 3 (0.1) 0 (0.0)
65–74 98 (7.8) 92 (7.3) 6 (0.5) 3 (0.2) 2 (0.2) 1 (0.1)
≥75 53 (13.2) 44 (11.0) 9 (2.2) 5 (1.3) 4 (1.0) 0 (0.0)
Overall unweighted 307 (6.5) 288 (6.1) 19 (0.4) 9 (0.2) 9 (0.2) 1 (0.0)
Overall weighted 86 095 (7.2) 78 950 (6.6) 7144 (0.6) 3618 (0.3) 3303 (0.3) 224 (0.0)
95% CI (overall weighted) 6.5 to 7.9 5.9 to 7.3 0.4 to 0.8 0.1 to 0.5 0.1 to 0.5 –
*Mixed AMD—subject has neovascular AMD in one eye and atrophic AMD in the other eye.
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aged 50 years or older. The prevalence of AMD (any form) in
ROI is estimated at 7.2%, after adjusting for different non-
response rates (and different attendance rates at the health
centres) in different age groups.
The prevalence estimates (and all other results presented in
this paper) were obtained from subjects with gradable photo-
graphs only. Including the 108 ungradable subjects, and assum-
ing these have the same prevalence rates within age groups as
the gradable subjects, leads to some changes in AMD sample
numbers within each age group, but also to changes in weights.
The net effect is an overall age-adjusted estimate of 7.17% for
any AMD, that is, practically identical to the estimate from the
gradable subjects only.
Different population-based studies reporting prevalence esti-
mates of AMD have adopted various photography/grading pro-
tocols and deﬁnitions for AMD. Table 7 provides AMD
prevalence estimates from other studies for comparison with
estimates from our TILDA study. Some large differences in
reported AMD prevalence are evident in table 7 and could be
either attributable to differences between the populations
studied or to differences in study design (eg, grading techniques,
photography protocols, sampling and recruitment strategies and
age range of sample). A recent meta-analysis of the prevalence
of AMD in populations of European ancestry found substantial
variability in prevalence rates between studies, with differences
in late AMD primarily due to differences in age proﬁle and
study design.22 For the purpose of emphasising the important
role of such variables on published ﬁndings, it is noteworthy
that the prevalence of early AMD was as high as 52.3% and
58.6% in the Greenland Inuit Eye Study23 and Prevalence of
Age-related Macular Degeneration in Italy study,24 respectively.
However, in our study, we estimate the prevalence of early
AMD in ROI to be 6.6%, consistent with many reports of eth-
nically comparable populations (eg, National Health and
Nutrition Examination Survey (NHANES) 2005–2008 US
population:11 5.7%).
The prevalence of late AMD in the current study was 0.6%,
consistent with some previous reports (eg, NHANES 2005–
2008 US population:11 0.8%; Visual Impairment Project:25
0.68%) but less than that reported by others (eg, Beaver Dam
Eye Study:18 1.6%; Rotterdam Study:12 1.7%). However, the
prevalence of neovascular AMD and atrophic AMD is known to
vary between studies. In our study, we report prevalence for
each of the two forms of late AMD (atrophic and neovascular)
to be equal (at 0.3% each), whereas some previous studies have
reported the atrophic form to be more common than the neo-
vascular form (eg, Reykjavik Eye Study:20 atrophic 3.2%, neo-
vascular 0.7%). In contrast, however, the neovascular form of
AMD has been reported to be more prevalent than the atrophic
form of the condition in many other studies (eg, Beaver Dam
Eye Study:18 atrophic 0.6%, neovascular 1.2%; Blue Mountains
Eye Study:19 atrophic 0.7%, neovascular 1.3%; Rotterdam
Study:12 atrophic 0.6%, neovascular 1.1%; European Eye
Study:26 atrophic 1.2%, neovascular 2.3%).
In general, we found that differences in prevalence of AMD
between demographic subgroups were not statistically signiﬁ-
cant, after controlling for age (tables 4 and 5). However, espe-
cially for the rarer forms of AMD, these ﬁndings are based on
small cell frequencies and should be treated circumspectly.
For both men and women in this study, the impact of age on
prevalence appears much stronger for the more severe forms of
the disease. For example, in table 4, the prevalence of late AMD
in the ≥75 age group (at 2.6%) is 5.2 times the prevalence
observed for the 60–74 age group for men and 3.8 times the
Ta
bl
e
4
Pr
ev
al
en
ce
of
ag
e-
re
la
te
d
m
ac
ul
ar
de
ge
ne
ra
tio
n
(A
M
D)
by
de
m
og
ra
ph
ic
su
bg
ro
up
s,
st
ra
tif
ie
d
by
ag
e
gr
ou
p
Ch
ar
ac
te
ris
tic
,n
(%
)
A
ny
A
M
D
Ea
rly
A
M
D
La
te
A
M
D
A
tr
op
hi
c
A
M
D
N
eo
va
sc
ul
ar
A
M
D
A
ge
gr
ou
ps
A
ge
gr
ou
ps
A
ge
gr
ou
ps
A
ge
gr
ou
ps
A
ge
gr
ou
ps
50
–
64
65
–
74
≥
75
50
–
64
65
–
74
≥
75
50
–
64
65
–
74
≥
75
50
–
64
65
–
74
≥
75
50
–
64
65
–
74
≥
75
G
en
de
r
M
al
e
71
(5
.2
)
47
(7
.8
)
21
(1
1.
1)
70
(5
.1
)
44
(7
.3
)
16
(8
.4
)
1
(0
.1
)
3
(0
.5
)
5
(2
.6
)
0
(0
.0
)
2
(0
.3
)
3
(1
.6
)
1
(0
.1
)
1
(0
.2
)
2
(1
.1
)
Fe
m
al
e
85
(4
.9
)
51
(7
.9
)
32
(1
5.
3)
82
(4
.8
)
48
(7
.4
)
28
(1
3.
4)
3
(0
.2
)
3
(0
.5
)
4
(1
.9
)
1
(0
.1
)
1
(0
.2
)
2
(1
.0
)
2
(0
.1
)
1
(0
.2
)
2
(1
.0
)
p
Va
lu
e
0.
77
1
0.
94
7
0.
21
1
0.
67
2
0.
92
7
0.
11
3
0.
43
5
0.
93
3
0.
63
0
0.
37
2
0.
52
4
0.
57
7
0.
70
0
0.
96
1
0.
92
4
Ed
uc
at
io
n
Pr
im
ar
y/
no
ne
28
(5
.7
)
34
(8
.5
)
15
(1
2.
0)
27
(5
.5
)
33
(8
.3
)
9
(7
.2
)
1
(0
.2
)
1
(0
.3
)
6
(4
.8
)
0
(0
.0
)
0
(0
.0
)
3
(2
.4
)
1
(0
.2
)
1
(0
.3
)
3
(2
.4
)
Se
co
nd
ar
y
72
(5
.2
)
30
(6
.9
)
21
(1
3.
8)
69
(4
.9
)
27
(6
.2
)
19
(1
2.
5)
3
(0
.2
)
3
(0
.7
)
2
(1
.3
)
1
(0
.1
)
1
(0
.2
)
1
(0
.7
)
2
(0
.1
)
1
(0
.2
)
1
(0
.7
)
Te
rti
ar
y
56
(4
.6
)
34
(8
.1
)
17
(1
4.
2)
56
(4
.6
)
32
(7
.6
)
16
(1
3.
3)
0
(0
.0
)
2
(0
.5
)
1
(0
.8
)
0
(0
.0
)
2
(0
.5
)
1
(0
.8
)
0
(0
.0
)
0
(0
.0
)
0
(0
.0
)
p
Va
lu
e
0.
62
8
0.
65
8
0.
86
3
0.
74
4
0.
50
1
0.
24
2
0.
27
7
0.
65
6
0.
06
9
0.
54
5
0.
37
7
0.
38
2
0.
35
6
0.
60
3
0.
14
7
Lo
ca
tio
n
Du
bl
in
33
(4
.0
)
27
(7
.0
)
21
(1
3.
3)
33
(4
.0
)
24
(6
.2
)
17
(1
0.
8)
0
(0
.0
)
3
(0
.8
)
4
(2
.5
)
0
(0
.0
)
1
(0
.3
)
2
(1
.3
)
0
(0
.0
)
2
(0
.5
)
2
(1
.3
)
O
th
er
ur
ba
n
48
(4
.9
)
27
(7
.8
)
18
(1
8.
4)
46
(5
.6
)
26
(7
.5
)
18
(1
8.
4)
2
(0
.2
)
1
(0
.3
)
0
(0
.0
)
1
(0
.1
)
1
(0
.3
)
0
(0
.0
)
1
(0
.1
)
0
(0
.0
)
0
(0
.0
)
Ru
ra
l
75
(5
.2
)
43
(8
.3
)
14
(9
.8
)
73
(5
.1
)
41
(7
.9
)
9
(6
.3
)
2
(0
.1
)
2
(0
.4
)
5
(3
.5
)
0
(0
.0
)
1
(0
.2
)
3
(2
.1
)
2
(0
.1
)
0
(0
.0
)
2
(1
.4
)
p
Va
lu
e
0.
18
5
0.
77
6
0.
15
6
0.
26
4
0.
61
8
0.
01
3
0.
37
9
0.
58
4
0.
19
1
0.
24
8
0.
95
5
0.
35
5
0.
56
9
0.
10
6
0.
51
5
Le
ve
lo
fs
ig
ni
fic
an
ce
se
t
at
p<
0.
05
;s
ta
tis
tic
al
sig
ni
fic
an
ce
te
st
ed
w
ith
χ2
te
st
fo
rc
on
tin
ge
nc
y
ta
bl
es
.
Bo
ld
sig
ni
fie
s
st
at
ist
ic
al
ly
sig
ni
fic
an
t
p
va
lu
e.
Du
bl
in
,r
es
id
en
ce
in
Du
bl
in
ci
ty
or
co
un
ty
;O
th
er
ur
ba
n,
re
sid
en
ce
in
ot
he
r
ur
ba
n,
an
ot
he
r
to
w
n
or
ci
ty
in
th
e
Re
pu
bl
ic
of
Ire
la
nd
;e
du
ca
tio
n,
le
ve
lo
fe
du
ca
tio
n;
lo
ca
tio
n,
lo
ca
tio
n
of
re
sid
en
ce
in
th
e
Re
pu
bl
ic
of
Ire
la
nd
;p
rim
ar
y/
no
ne
,s
ub
je
ct
s
w
ho
di
d
no
t
ha
ve
ed
uc
at
io
n
an
d
th
os
e
w
ith
on
ly
pr
im
ar
y
ed
uc
at
io
n;
ru
ra
l,
re
sid
en
ce
in
ru
ra
la
re
a
in
th
e
Re
pu
bl
ic
of
Ire
la
nd
;s
ec
on
da
ry
,s
ub
je
ct
s
w
ho
co
m
pl
et
ed
a
ju
ni
or
ce
rti
fic
at
e
or
le
av
in
g
ce
rti
fic
at
e
or
eq
ui
va
le
nt
;t
er
tia
ry
,s
ub
je
ct
s
w
ho
co
m
pl
et
ed
a
di
pl
om
a,
fir
st
de
gr
ee
or
hi
gh
er
de
gr
ee
.
Akuffo KO, et al. Br J Ophthalmol 2015;99:1037–1044. doi:10.1136/bjophthalmol-2014-305768 1041
Clinical science
group.bmj.com on November 9, 2017 - Published by http://bjo.bmj.com/Downloaded from 
observed prevalence for women. In contrast, for early AMD,
the corresponding risk ratios are 1.2 and 1.8 for men and
women, respectively. Similarly, in table 5, prevalence of soft
drusen in the ≥75 group is 1.5 times and 2.1 times the preva-
lence observed in the 60–74 group for men and women,
respectively, whereas the corresponding risk ratios for hard
drusen are just 0.4 and 1.4 for men and women, respectively.
While primarily concerned with the prevalence of AMD, we
also investigated possible associations with this condition, espe-
cially for variables that have been previously identiﬁed as risk
factors for AMD. In this regard, we report that the prevalence
of AMD increases with increasing age, consistent with all other
studies.18 19 Also, family history for AMD was strongly asso-
ciated with prevalence of this condition, consistent with other
studies.27 28 In fact, in the 65–74 and ≥75 age groups, the
prevalence of AMD is strikingly greater for subjects who
reported a family history of this condition. Self-reported data
with respect to family history for AMD are problematic for the
following reasons: reporting of AMD among siblings is subject
to inﬂuence by the number of siblings; reporting of AMD
among parents is subject to inﬂuence by the longevity of those
parents; reporting of AMD among participants who were
adopted will be irrelevant with respect to a genetic predispos-
ition for AMD; and ﬁnally, reporting of early AMD is likely to
be under-represented because it is typically asymptomatic.
Nevertheless, and with full appreciation of these limitations,
and given that we excluded subjects who replied that they
did not know whether or not a ﬁrst-degree relative suffered
from AMD, we believe that our ﬁndings that self-reported
family history of AMD is a risk factor for the condition are
important.
However, with respect to other potential risk factors for
which no statistically signiﬁcant associations with AMD were
observed in the current study, it should be appreciated that con-
trolling for age in the logistic regression analyses, and stratifying
AMD prevalence by age group, may have contributed to the
non-identiﬁcation of some potentially signiﬁcant associations
with AMD.
The strengths of our study include (1) the use of a
population-representative cohort of subjects aged 50 years and
older in ROI; (2) the study population is racially homogeneous,
over 99% being white; and (3) retinal photographs were graded
in a masked fashion using standard protocols by the same
person and therefore reducing intergrader variability. The large
sample size (nearly 5000) could also be considered a strength,
but the need to stratify by age group meant that, for some ana-
lyses, subgroup sizes were small.
The limitations of this study include the use of monoscopic
retinal photographs through undilated pupils, rendering it difﬁ-
cult to obtain quality photographs in the presence of signiﬁcant
media opacities. The TILDA investigators elected to use mono-
scopic retinal photographs in the study because other health
Table 5 Prevalence of drusen by demographic subgroups, stratified by age group
Characteristic, n (%)
Hard drusen (<63 mm)* Soft drusen (>125 mm)
Age groups Age groups
50–64 65–74 ≥75 50–64 65–74 ≥75
Gender
Male 36 (2.6) 15 (2.5) 2 (1.1) 34 (2.5) 29 (4.8) 14 (7.4)
Female 49 (2.9) 20 (3.1) 9 (4.3) 33 (1.9) 28 (4.3) 19 (9.1)
p Value 0.702 0.515 0.047 0.289 0.688 0.533
Education
Primary/none 18 (3.7) 13 (3.3) 4 (3.2) 9 (1.8) 20 (5.0) 5 (4.0)
Secondary 40 (2.9) 11 (2.5) 4 (2.6) 29 (2.1) 16 (3.7) 15 (9.9)
Tertiary 27 (2.2) 11 (2.6) 3 (2.5) 29 (2.4) 21 (5.0) 13 (10.8)
p Value 0.240 0.789 0.938 0.735 0.559 0.104
Location
Dublin 23 (2.8) 10 (2.6) 3 (1.9) 10 (1.2) 14 (3.6) 14 (8.9)
Other urban 21 (2.6) 11 (3.2) 5 (5.1) 25 (3.1) 15 (4.3) 13 (13.3)
Rural 41 (2.9) 13 (2.5) 3 (2.1) 32 (2.2) 28 (5.4) 6 (4.2)
p Value 0.929 0.816 0.262 0.033 0.445 0.040
Level of significance set at p<0.05; statistical significance tested with χ2 test for contingency tables.
Bold signifies statistically significant p value.
*More than 10 hard drusen (<63 mm).
Dublin, residence in Dublin city or county; Other urban, residence in other urban, another town or city in the Republic of Ireland; education, level of education; location, location of
residence in the Republic of Ireland; primary/none, subjects who did not have education and those with only primary education; rural, residence in rural area in the Republic of Ireland;
secondary, subjects who completed a junior certificate or leaving certificate or equivalent; tertiary, subjects who completed a diploma, first degree or higher degree.
Table 6 Risk factors for prevalence of age-related macular
degeneration (AMD), stratified by age group
Characteristic, n (%)
Any AMD
Age groups
50–64 65–74 ≥75
Smoking
Never 77 (5.4) 39 (6.7) 24 (13.0)
Past 50 (4.4) 44 (8.5) 25 (13.1)
Current 29 (5.5) 15 (10.1) 4 (16.7)
p Value 0.420 0.290 0.881
Family history
No 134 (5.0) 75 (7.2) 40 (11.7)
Yes 9 (6.1) 12 (14.5) 8 (33.3)
p Value 0.564 0.017 0.002
Level of significance set at p<0.05; statistical significance tested with χ2 test for
contingency tables.
Bold signifies statistically significant p value.
Family history, subjects who reported a family history of AMD—family history was
defined as having a first-degree relative, that is, parent or sibling with AMD; smoking,
smoking status of subjects classified as never (no reported history of smoking), past
(past smokers) and current (current smokers).
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assessment measures (eg, gait) were to be conducted immedi-
ately following retinal photography, and the results of such tests
would have been inﬂuenced and confounded by pharmaco-
logical pupillary dilation. Also, subjects with ungradable images
were more likely to be older and have poor vision, although
(upon investigation) this did not appear to have much effect on
our prevalence estimates.
The response rate in the TILDA study (62% of eligible house-
holds participated) is in line with other national household
surveys of older people, for example, in the Survey of Health,
Ageing and Retirement in Europe, the average response rate
across all countries was 55%.29 Moreover, a non-response rate of
this magnitude had been anticipated (from pilot surveys prior to
the main survey) and built into the sample size calculations for
the TILDA study. However, non-attendance at health centres
reduced the effective participation rate further, so that just 5035
of 8175 participants (61.6%), who were successfully enrolled in
the broader TILDA study, actually took part in this AMD study;
this represents just 38% of the individuals originally selected.
This has to be acknowledged as a weakness of our study, although
we were able to adjust our prevalence calculations, to take
account of the distorted sample age structure that arose from this
non-participation. Of note, while many of the studies listed in
table 7 reported much higher response rates than our AMD study
(eg, 83.1% for the Beaver Dam Study), most of these were not
nationally representative population-based studies and are not
directly comparable.
In conclusion, this study reports the prevalence of AMD in
ROI for the ﬁrst time and will inform healthcare providers and
planners involved in the delivery of care to those suffering with
this condition.
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Table 7 Prevalence of age-related macular degeneration (AMD) in comparable population-based studies
Study name Country Age group (year) Early AMD (%) Late AMD (%) Atrophic AMD (%) Neovascular AMD (%)
Baltimore Eye Survey* USA 40–49 0.0 0.0 0.0
1985–198817 50–59 0.5 0.2 0.4
60–69 0.7 0.7 0.0
70–79 2.9 1.8 1.6
80+ 7.0 4.0 5.6
Beaver Dam Eye Study USA 43–54 8.4 0.1
1988–199018 55–64 13.8 0.6
65–74 18.0 1.4
75+ 29.7 7.1
Blue Mountains Eye Study Australia 49–54 1.3 0.0
1992–199319 55–64 2.6 0.2
65–74 8.5 0.7
75–84 15.5 5.4
85+ 28.0 18.5
Reykjavik Eye Study Iceland 50–59 8.9 0.3 0.3 0.0
199620 60–69 16.4 1.2 1.2 0.0
70–79 27.5 5.8 5.3 0.5
>80 37.1 30.8 25.0 9.8
MESA* USA 45–54 1.8 0.0
2000–200221 55–64 2.8 0.1
65–74 5.5 0.3
75–84 13.3 2.9
TILDA Study ROI 50–64 4.9 0.1 0.1 0.1
2009–2011 65–74 7.3 0.5 0.2 0.2
≥75 11.0 2.2 1.3 1.0
*Data on only white participants.
MESA, Multi-ethnic Study of Atherosclerosis; ROI, Republic of Ireland; TILDA, the Irish Longitudinal Study on Ageing.
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